A Phase 3 interventional study of rFVIII (BAY81-8973) on demand and rFVIII (BAY81-8973) prophylaxis low-dose in Hemophilia A, sponsored by Bayer. Completed at 47 sites in 18 countries. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 3, and was the 12th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:
Runhui WU · Sites in China
Ages 0–18 · Men only
By country, each count listing its studies:
antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2001; this study’s year is marked. 2 started in 2011.
This study's enrollment of 80 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 50 across the 21 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
57 studies in Hemophilia A by Bayer: 3 open now, 6 under way, none of them phase 3. Of 50 finished, 14 (28%) have results posted.
Among the 57 studies in Hemophilia A by Bayer, this one is the 6th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 17th registered.
Bayer’s Hemophilia A studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 57 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
The objective of the trial is to demonstrate that 2-3 times per week prophylaxis therapy with BAY81-8973 is superior to on-demand therapy with BAY81-8973 in patients with severe Hemophilia A. The hypothesis is that prophylaxis will result in fewer bleeds than on-demand treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
Biological: rFVIII (BAY81-8973) on demand
Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
Biological: rFVIII (BAY81-8973) on demand
Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
Biological: rFVIII (BAY81-8973) prophylaxis low-dose
Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
Biological: rFVIII (BAY81-8973) prophylaxis low-dose
Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
Biological: rFVIII (BAY81-8973) prophylaxis high-dose
Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
Biological: rFVIII (BAY81-8973) prophylaxis high-dose
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
Drug pages: Antihemophilic factor, human recombinant · F8 protein, human
Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
Annualized Number of All Bleeds
The annualized number of bleeds experienced by participants
Time frame: Up to 12 months (6 months per mode of potency assignment according to the randomized cross-over design)
Annualized Number of All Bleeds During CS/EP Period
The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/EP
Time frame: Up to 6 months (6 months on CS/EP potency assignment)
Annualized Number of All Bleeds During CS/ADJ Period
The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/ADJ
Time frame: Up to 6 months (6 months on CS/ADJ potency assignment)
Percentage of Bleeds Per Participant Controlled With ≤ 2 Injections in Participants Treated on Demand With rFVIII (BAY81-8973)
The percentage of bleeds per participant on on-demand treatment that stopped after two or fewer injections
Time frame: Up to 12 months (6 months per mode of potency assignment according to the randomized cross-over design)
Number of Bleeds During Treatment
The number of bleeds experienced by each participant
Time frame: 12 months
Number of Participants With Inhibitory Antibody Formation
A test to ensure that participants have not developed antibodies that will interfere with the action of rFVIII (BAY81-8973)
Time frame: 3, 6, 9 and 12 months after baseline
Participants were recruited from specialized hemophilia treatment centers.
| Milestone | On Demand, BAY 81-8973 Potency First EP Then ADJ | On Demand, BAY 81-8973 Potency First ADJ Then EP | Low Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJ | Low Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP | High Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJ | High Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP |
|---|---|---|---|---|---|---|
| Started | 11 | 10 | 14 | 16 | 16 | 16 |
| Participants received treatment | 11 | 10 | 13 | 15 | 16 | 15 |
| Completed | 10 | 10 | 13 | 15 | 16 | 15 |
| Not completed | 1 | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study medication | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | On Demand, BAY 81-8973 Potency First EP Then ADJ | On Demand, BAY 81-8973 Potency First ADJ Then EP | Low Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJ | Low Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP | High Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJ | High Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 13 | 15 | 16 | 15 |
| Completed | 10 | 10 | 13 | 15 | 16 | 15 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | On Demand, BAY 81-8973 Potency First EP Then ADJ | On Demand, BAY 81-8973 Potency First ADJ Then EP | Low Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJ | Low Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP | High Dose Prophylaxis, BAY 81-8973 Potency First EP Then ADJ | High Dose Prophylaxis, BAY 81-8973 Potency First ADJ Then EP |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 13 | 15 | 16 | 15 |
| Completed | 10 | 10 | 13 | 15 | 16 | 15 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
The annualized number of bleeds experienced by participants
| Bleeds per year per participant | rFVIII (BAY81-8973) on Demand | rFVIII (BAY81-8973) Prophylaxis Treatment |
|---|---|---|
| Annualized Number of All Bleeds | 57.7 ± 24.6 | 4.9 ± 6.8 |
The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/EP
| Bleeds per year per participant | rFVIII (BAY81-8973) on Demand Assayed by CS/EP | rFVIII (BAY81-8973) Prophylaxis Treatment Assayed by CS/EP |
|---|---|---|
| Annualized Number of All Bleeds During CS/EP Period | 57.6 ± 24.3 | 5.1 ± 8.0 |
The annualized number of bleeds experienced by participants while they were taking rFVIII (BAY81-8973) assayed by CS/ADJ
| Bleeds per year per participant | rFVIII (BAY81-8973) on Demand Assayed by CS/ADJ | rFVIII (BAY81-8973) Prophylaxis Treatment Assayed by CS/ADJ |
|---|---|---|
| Annualized Number of All Bleeds During CS/ADJ Period | 59.7 ± 25.1 | 4.8 ± 6.8 |
The percentage of bleeds per participant on on-demand treatment that stopped after two or fewer injections
| Percentage of bleeds | rFVIII (BAY81-8973) on Demand Assayed by CS/EP | rFVIII (BAY81-8973) on Demand Assayed by CS/ADJ |
|---|---|---|
| Percentage of Bleeds Per Participant Controlled With ≤ 2 Injections in Participants Treated on Demand With rFVIII (BAY81-8973) | 96.8 (77.8 to 100.0) | 100.0 (65.7 to 100.0) |
The number of bleeds experienced by each participant
| Bleeds | rFVIII (BAY81-8973) on Demand | rFVIII (BAY81-8973) Prophylaxis Low-dose | rFVIII (BAY81-8973) Prophylaxis High-dose |
|---|---|---|---|
| Number of Bleeds During Treatment | 60.0 (42.0 to 77.0) | 4.0 (0.0 to 8.0) | 2.0 (0.0 to 5.0) |
A test to ensure that participants have not developed antibodies that will interfere with the action of rFVIII (BAY81-8973)
| Participants | rFVIII (BAY81-8973) on Demand | rFVIII (BAY81-8973) Prophylaxis Low-dose | rFVIII (BAY81-8973) Prophylaxis High-dose |
|---|---|---|---|
| 3 months after baseline | 0 | 0 | 0 |
| 6 months after baseline | 0 | 0 | 0 |
| 9 months after baseline | 0 | 0 | 0 |
| 12 months after baseline | 0 | 0 | 0 |
Collected over Treatment-emergent adverse event data reported here were collected from start of first treatment up to 12.5 months (end of observation period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rFVIII (BAY81-8973) Treatment | — | 2/80 (2.5%) | 23/80 (28.8%) |
| Event | rFVIII (BAY81-8973) Treatment |
|---|---|
| Head injuryInjury, poisoning and procedural complications | 1/80 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/80 |
| Event | rFVIII (BAY81-8973) Treatment |
|---|---|
| NasopharyngitisInfections and infestations | 13/80 |
| Upper respiratory tract infectionInfections and infestations | 6/80 |
| HeadacheNervous system disorders | 5/80 |
| InfluenzaInfections and infestations | 4/80 |
| InsomniaPsychiatric disorders | 4/80 |
| Age, Continuous(years) | rFVIII (BAY81-8973) on Demand | rFVIII (BAY81-8973) Prophylaxis Low-dose | rFVIII (BAY81-8973) Prophylaxis High-dose | Total |
|---|---|---|---|---|
| Mean | 31.4 ± 10.9 | 28.8 ± 10.9 | 29.1 ± 11.5 | 29.6 ± 11.0 |
| Sex: Female, Male(Participants) | rFVIII (BAY81-8973) on Demand | rFVIII (BAY81-8973) Prophylaxis Low-dose | rFVIII (BAY81-8973) Prophylaxis High-dose | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 21 | 28 | 31 | 80 |
The record gives a start of Jan 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human